VIVOS INC

Vivos Inc. announced a Stock Purchase and Exchange Agreement with a Board Director, Carl Cadwell. Cadwell purchased 250,000 shares of Series D Convertible Preferred Stock for $250,000 and exchanged 385,302 shares of Series C Convertible Preferred Stock for an equal number of Series D shares. This transaction results in no outstanding Series C Preferred Stock and 635,302 shares of Series D Preferred outstanding.

VIVOS INC reported a net loss of $2.01 million for the six months ended June 30, 2026, an increase from $1.48 million in the prior year, primarily due to a loss on issuance of shares and warrant exchange. Despite a revenue increase to $72,468 for the period, the company's recurring losses and insufficient cash raise significant doubt about its ability to continue as a going concern. VIVOS INC requires $3 million annually for operations and an additional $9 million over 36 months for strategic initiatives, including FDA approval for RadioGel® and expansion of IsoPet® animal therapy.

Vivos Inc. reported a net loss of $(1.18) million for Q1 2026, an increase from $(0.83) million in Q1 2025, primarily due to a $(651,628) loss on issuance of shares and warrant exchange. Despite this, the company saw a revenue increase to $36,068 from $26,748 year-over-year and significantly reduced operating expenses. The company's cash position improved to $2.53 million, bolstered by $1.55 million in financing activities, but it continues to face substantial doubt about its ability to continue as a going concern, requiring $3 million annually for operations.